Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Perry who wrote (5098)	8/23/1998 12:29:00 AM
From: Anthony Wong	Respond to of 9523

Perry, the œ100 million in UK sales in five years' time isn't a misprint. Pfizer is deliberately underestimating the demand, as evident from these 2 paragraphs in an earlier article (August 17) in The Times: The tax income from Viagra will offset the cost of the drug to the National Health Service, which doctors at last month's meeting of the British Medical Association suggested could be œ1 billion or more. This would impose an unbearable strain on the total NHS drugs budget of œ5.5 billion. The widely publicised estimate has prompted calls for Viagra to be rationed, making it available only through consultants and urologists. Pfizer is privately alarmed by the œ1 billion estimate, which it claims is much too high. In lobbying the Department of Health and the drug-pricing authorities, the company is arguing that demand will turn out to be much more modest - partly because of the conservatism towards new drugs among the patient population in Britain, and the continuing reluctance of men to admit to having impotence. Anthony